This study aimed to describe selected epidemiological aspects of horses with acute onset of fever and respiratory signs testing qPCR-positive for S. equi and to determine the effect of vaccination against S. equi on qPCR status. Horses with acute onset of fever and respiratory signs from all regions of the United States were included in a voluntary biosurveillance program from 2008 to 2020 and nasal secretions were tested via qPCR for S. equi and common respiratory viruses. A total of 715/9409 equids (7.6%) tested qPCR-positive for S. equi, with 226 horses showing coinfections with EIV, EHV-1, EHV-4, and ERBV. The median age for the S. equi qPCR-positive horses was 8 ± 4 years and there was significant difference when compared to the median age of the S. equi qPCR-negative horses (6 ± 2 years; p = 0.004). Quarter Horse, Warmblood, and Thoroughbred were the more frequent breed in this horse population, and these breeds were more likely to test qPCR-positive for S. equi compared to other breeds. There was not statistical difference for sex between S. equi qPCR-positive and qPCR-negative horses. Horses used for competition and ranch/farm use were more likely to test qPCR-positive for S. equi (p = 0.006). Horses that tested S. equi qPCR-positive were more likely to display nasal discharge, fever, lethargy, anorexia, and ocular discharge compared to horses that tested S. equi qPCR-negative (p = 0.001). Vaccination against S. equi was associated with a lower frequency of S. equi qPCR-positive status.
18 January 2022 in Journal of Veterinary Internal Medicine
Background Increased concentration of haptoglobin (Hp) in serum is associated with survival of critically ill humans and horses. High serum activity of liver-derived enzyme is associated with sepsis in children and foals. Hypothesis/Objectives Investigate whether admission serum Hp and glutamic dehydrogenase (GLDH) are associated with systemic inflammatory response syndrome (SIRS) and survival of sick calves. Animals One hundred two calves. Methods Retrospective cross-sectional study. Electronic medical records from all calves <30 days of age admitted to a teaching hospital for 8 years were reviewed. The signalment, clinicopathological findings, the presence of SIRS, final diagnosis, hospitalization time and outcome were recorded. A Cox proportional hazard ratio (HzR) were calculated to assess the association between clinicopathological variables and survival to discharge. Results Serum Hp concentrations were similar between SIRS (0.29 g/L; range, 0.05-3.6) and non-SIRS calves (0.22 g/L; range, 0-4.2; P = .62). GLDH activity was similar between SIRS (12 U/L; range, 1-1025) and non-SIRS calves (9 U/L; range, 2-137; P = .2). Absent suckle reflex (HzR: 6.44, 95% CI: 1.44-28.86), heart rate (HR) < 100 beats per minute (bpm; HzR: 12.2; 95% CI: 2.54-58.62), HR > 140 bpm (HzR: 3.59, 95% CI: 1.05-12.33), neutrophil count <1.7 × 109/L (HzR: 7.36; 95% CI: 2.03-26.66) and increased gamma-glutamyl transferase activity (every 50-unit, HzR: 1.12; 95% CI: 1.03-1.21) were predictive of nonsurvival. Conclusions and Clinical Importance The use of Hp and GLDH for prediction of survival in sick calves cannot be recommended at this time.
17 November 2020 in Tropical Animal Health and Production
Background: Current treatment options for equine gastric ulcer syndrome (EGUS), such as omeprazole—a proton pump inhibitor (PPI)—have notable limitations, including the need for administration on an empty stomach. Potassium‐competitive acid blockers (P‐CABs), such as vonoprazan, are a newer class of acid suppressants that offer several advantages over PPIs in humans and may provide similar benefits in horses. Objectives: To describe the pharmacokinetics and effect of a single oral dose of vonoprazan on intragastric pH in horses. We hypothesised that vonoprazan would follow linear kinetics across the doses studied and effectively increase intragastric pH. Study Design: Prospective, randomised four‐way balanced crossover study. Methods: Six horses received vonoprazan (0.5 and 1 mg/kg), omeprazole (4 mg/kg) and water (60 mL). Blood samples were collected prior to and up to 72 h post‐administration. Plasma vonoprazan concentrations were measured using liquid chromatography–tandem mass spectrometry, and non‐compartmental and compartmental pharmacokinetic analyses were performed. Intragastric pH was continuously recorded 12 h before and 24 h after each treatment. The percentage of time pH remained above 4 was compared among treatments. Results: For 0.5 and 1 mg/kg vonoprazan, respectively, Cmax was 23.7 ± 14.0 and 55.8 ± 18.1 ng/mL (mean ± SD); Tmax was 0.875 (0.25–3.0) and 0.625 (0.08–1.0) h (median and range); and terminal half‐life was 6.12 ± 1.65 and 6.29 ± 1.86 h (mean ± SD). At 1 mg/kg, vonoprazan significantly increased the percentage of time pH >4 compared to pre‐treatment (91.85% vs. 85.5%; p = 0.007) and placebo (90.28 ± 5.6% vs. 5.68 ± 39%; p = 0.021). Main Limitation: Small sample size which may impact clinical applicability of observed changes and potential variability in pH probe positioning. Conclusion: Vonoprazan was well tolerated and effectively increased and maintained intragastric pH above 4 at the 1 mg/kg dose in horses.